title: Relapse after treatment with peginterferon alpha-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B.
authors.forename: H J
authors.initials: HJ
authors.lastname: Flink
authors.forename: E H C J
authors.initials: EH
authors.lastname: Buster
authors.forename: I
authors.initials: I
authors.lastname: Merican
authors.forename: F
authors.initials: F
authors.lastname: Nevens
authors.forename: G
authors.initials: G
authors.lastname: Kitis
authors.forename: J
authors.initials: J
authors.lastname: Cianciara
authors.forename: R A
authors.initials: RA
authors.lastname: de Vries
authors.forename: B E
authors.initials: BE
authors.lastname: Hansen
authors.forename: S W
authors.initials: SW
authors.lastname: Schalm
authors.forename: H L A
authors.initials: HL
authors.lastname: Janssen
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006513:Hepatitis B e Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012008:Recurrence; D012307:Risk Factors
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D019259:Lamivudine; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b